165 related articles for article (PubMed ID: 10528081)
21. Determination of extracellular methotrexate tissue levels by microdialysis in a rat model.
Ekstrøm PO; Andersen A; Warren DJ; Giercksky KE; Slørdal L
Cancer Chemother Pharmacol; 1996; 37(5):394-400. PubMed ID: 8599860
[TBL] [Abstract][Full Text] [Related]
22. In vivo anticancer activity of methotrexate-loaded layered double hydroxide nanoparticles.
Choi SJ; Oh JM; Chung HE; Hong SH; Kim IH; Choy JH
Curr Pharm Des; 2013; 19(41):7196-202. PubMed ID: 23489199
[TBL] [Abstract][Full Text] [Related]
23. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates.
Hudecz F; Clegg JA; Kajtár J; Embleton MJ; Pimm MV; Szekerke M; Baldwin RW
Bioconjug Chem; 1993; 4(1):25-33. PubMed ID: 8431509
[TBL] [Abstract][Full Text] [Related]
24. Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes.
Mao SJ; Hou SX; He R; Zhang LK; Wei DP; Bi YQ; Jin H
World J Gastroenterol; 2005 May; 11(20):3075-9. PubMed ID: 15918193
[TBL] [Abstract][Full Text] [Related]
25. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate.
Kurmi BD; Gajbhiye V; Kayat J; Jain NK
J Pharm Sci; 2011 Jun; 100(6):2311-20. PubMed ID: 21491447
[TBL] [Abstract][Full Text] [Related]
26. Ceramic core with polymer corona hybrid nanocarrier for the treatment of osteosarcoma with co-delivery of protein and anti-cancer drug.
Prasad SR; Kumar TSS; Jayakrishnan A
Nanotechnology; 2018 Jan; 29(1):015101. PubMed ID: 29130895
[TBL] [Abstract][Full Text] [Related]
27. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
28. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.
Wunder A; Müller-Ladner U; Stelzer EH; Funk J; Neumann E; Stehle G; Pap T; Sinn H; Gay S; Fiehn C
J Immunol; 2003 May; 170(9):4793-801. PubMed ID: 12707361
[TBL] [Abstract][Full Text] [Related]
29. Galactosylated bovine serum albumin nanoparticles for parenteral delivery of oridonin: tissue distribution and pharmacokinetic studies.
Li C; Zhang D; Guo Y; Guo H; Li T; Hao L; Zheng D; Liu G; Zhang Q
J Microencapsul; 2014; 31(6):573-8. PubMed ID: 24697186
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.
Ogawara K; Nishikawa M; Takakura Y; Hashida M
J Control Release; 1998 Jan; 50(1-3):309-17. PubMed ID: 9685898
[TBL] [Abstract][Full Text] [Related]
31. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
32. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Permeation of Methotrexate via Loading into Ultra-permeable Niosomal Vesicles: Fabrication, Statistical Optimization, Ex Vivo Studies, and In Vivo Skin Deposition and Tolerability.
Al-Mahallawi AM; Fares AR; Abd-Elsalam WH
AAPS PharmSciTech; 2019 Apr; 20(5):171. PubMed ID: 31004239
[TBL] [Abstract][Full Text] [Related]
34. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin.
Li C; Zhang D; Guo H; Hao L; Zheng D; Liu G; Shen J; Tian X; Zhang Q
Int J Pharm; 2013 May; 448(1):79-86. PubMed ID: 23518367
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and characterization of methotrexate polyethylene glycol esters as a drug delivery system.
Yousefi G; Foroutan SM; Zarghi A; Shafaati A
Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):147-53. PubMed ID: 20118571
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma.
Ruckmani K; Sivakumar M; Ganeshkumar PA
J Nanosci Nanotechnol; 2006; 6(9-10):2991-5. PubMed ID: 17048509
[TBL] [Abstract][Full Text] [Related]
37. Percutaneous absorption and disposition studies of methotrexate in rabbits and rats.
Lu G; Jun HW; Suh H
Biopharm Drug Dispos; 1997 Jul; 18(5):409-22. PubMed ID: 9210979
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate loaded self stabilized calcium phosphate nanoparticles: a novel inorganic carrier for intracellular drug delivery.
Mukesh U; Kulkarni V; Tushar R; Murthy RS
J Biomed Nanotechnol; 2009 Feb; 5(1):99-105. PubMed ID: 20055112
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment.
Chu BC; Howell SB
J Pharmacol Exp Ther; 1981 Nov; 219(2):389-93. PubMed ID: 6974776
[TBL] [Abstract][Full Text] [Related]
40. In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma.
Ray S; Saha S; Sa B; Chakraborty J
Drug Deliv Transl Res; 2017 Apr; 7(2):259-275. PubMed ID: 28050892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
